Profile data is unavailable for this security.
About the company
Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.
- Revenue in AUD (TTM)645.68m
- Net income in AUD49.19m
- Incorporated2017
- Employees234.00
- LocationTelix Pharmaceuticals LtdSuite 401 55 Flemington RoadNorth MelbourneMELBOURNE 3051AustraliaAUS
- Websitehttps://telixpharma.com/
Mergers & acquisitions
| Acquired company | TLX:ASX since announced | Transaction value |
|---|---|---|
| RLS (USA) Inc | -- | 250.00m |
| ARTMS Inc | -- | 82.00m |
| IsoTherapeutics Group LLC | -- | 12.90m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptidream Inc | 553.45m | 216.61m | 3.71bn | 603.00 | 17.10 | 6.30 | 15.45 | 6.71 | 167.15 | 167.15 | 427.44 | 453.44 | 0.7217 | 4.49 | 2.97 | 91,906,740.00 | 28.25 | -- | 33.81 | -- | 77.98 | -- | 39.14 | -- | 3.23 | 14.72 | 0.2626 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| Dizal Jiangsu Pharmaceutical Co Ltd | 62.17m | -197.82m | 3.84bn | 581.00 | -- | 29.91 | -- | 61.78 | -2.29 | -2.29 | 0.7174 | 1.47 | 0.1742 | 0.4174 | 4.62 | 507,467.80 | -60.62 | -46.02 | -81.84 | -52.99 | 96.75 | 57.53 | -347.91 | -2,081.54 | 1.81 | -- | 0.5253 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
| Sinocelltech Group Ltd | 502.65m | -27.93m | 3.88bn | 2.33k | -- | -- | -- | 7.73 | -0.2974 | -0.2974 | 5.35 | -1.03 | 0.818 | 0.4037 | 5.81 | 1,021,836.00 | -4.55 | -40.17 | -13.68 | -74.63 | 96.26 | 95.42 | -5.56 | -108.20 | 0.5057 | 4.62 | 1.19 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 600.07m | 230.22m | 5.24bn | 1.04k | 22.74 | 5.50 | -- | 8.72 | 2.43 | 2.43 | 6.32 | 10.03 | 0.6579 | 3.28 | 10.58 | 2,726,042.00 | 25.24 | 0.6405 | 27.43 | 0.6933 | 94.47 | 96.42 | 38.37 | 2.54 | 7.88 | -- | 0.0003 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Genscript Biotech Corp | 1.49bn | -261.96m | 5.89bn | 7.28k | -- | 3.27 | -- | 3.94 | -0.6495 | -0.6495 | 3.71 | 4.44 | 0.3006 | 9.15 | 7.99 | 1,130,268.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Syngene International Ltd | 611.42m | 86.74m | 6.14bn | 6.51k | 71.00 | -- | 37.75 | 10.04 | 12.24 | 12.24 | 86.29 | -- | -- | -- | -- | 5,330,569.00 | -- | 8.62 | -- | 11.43 | 72.89 | 71.13 | 14.19 | 16.22 | -- | 7.57 | -- | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| Telix Pharmaceuticals Ltd | 645.68m | 49.19m | 6.86bn | 234.00 | 136.87 | 16.95 | 121.52 | 10.62 | 0.1497 | 0.1497 | 1.96 | 1.21 | 1.22 | 11.36 | 8.61 | -- | 9.31 | -29.08 | 15.01 | -40.27 | 61.80 | 61.64 | 7.62 | -37.14 | 0.8687 | -- | 0.052 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
| Biocon Ltd | 2.60bn | 278.52m | 7.17bn | 3.68k | 25.75 | -- | 11.22 | 2.76 | 13.20 | 13.20 | 123.37 | -- | -- | -- | -- | 40,114,100.00 | -- | 3.20 | -- | 4.48 | 67.01 | 62.04 | 13.62 | 9.37 | -- | 1.54 | -- | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 395.85m | -49.09m | 9.19bn | 1.54k | -- | 13.58 | -- | 23.21 | -1.14 | -1.14 | 9.39 | 15.94 | 0.5869 | 9.46 | 167.74 | 1,468,051.00 | -7.28 | -- | -16.56 | -- | 61.81 | -- | -12.40 | -- | 5.59 | -- | 0.0118 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| PharmaEssentia Corp | 317.95m | 60.92m | 9.84bn | 131.00 | 153.28 | 8.22 | 128.39 | 30.95 | 4.09 | 4.09 | 21.42 | 76.26 | 0.2478 | 0.6845 | 4.22 | -- | 4.75 | -16.79 | 5.08 | -19.66 | 87.46 | 76.47 | 19.16 | -79.56 | 12.10 | -- | 0.0408 | -- | 77.15 | 186.97 | 54.62 | -- | 66.34 | -- |
| Holder | Shares | % Held |
|---|---|---|
| State Street Global Advisors, Australia, Ltd.as of 05 Aug 2024 | 10.24m | 3.06% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 10.06m | 3.01% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 5.21m | 1.56% |
| Vanguard Investments Australia Ltd.as of 30 Jun 2024 | 4.97m | 1.49% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 3.34m | 1.00% |
| Netwealth Investments Ltd.as of 24 Jan 2024 | 1.94m | 0.58% |
| State Street Global Advisors Trust Co.as of 05 Aug 2024 | 1.72m | 0.52% |
| BetaShares Capital Ltd.as of 31 Jul 2024 | 1.48m | 0.44% |
| AllianceBernstein LPas of 28 Jun 2024 | 1.22m | 0.37% |
| Portland Investment Counsel, Inc.as of 31 Mar 2024 | 1.09m | 0.33% |
